Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Boosted by National Pension Service

National Pension Service increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 3.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 369,547 shares of the medical equipment provider's stock after purchasing an additional 13,612 shares during the period. National Pension Service owned approximately 0.18% of Zimmer Biomet worth $39,893,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in ZBH. Crewe Advisors LLC acquired a new position in Zimmer Biomet during the first quarter worth about $31,000. J.Safra Asset Management Corp raised its holdings in Zimmer Biomet by 712.1% during the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 235 shares during the last quarter. Bangor Savings Bank purchased a new stake in Zimmer Biomet during the third quarter worth $31,000. Family Firm Inc. acquired a new stake in Zimmer Biomet in the second quarter valued at $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth $43,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Down 1.3 %

NYSE:ZBH traded down $1.48 during mid-day trading on Thursday, hitting $108.69. The company had a trading volume of 1,431,373 shares, compared to its average volume of 1,492,417. Zimmer Biomet Holdings, Inc. has a 1 year low of $101.47 and a 1 year high of $133.90. The business has a fifty day simple moving average of $106.64 and a 200-day simple moving average of $110.58. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $21.64 billion, a price-to-earnings ratio of 20.71, a PEG ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet's revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.65 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date was Monday, September 30th. Zimmer Biomet's payout ratio is 18.25%.

Analyst Ratings Changes

A number of brokerages have issued reports on ZBH. Oppenheimer cut their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating for the company in a research report on Tuesday, October 15th. Evercore ISI dropped their price target on Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. Wells Fargo & Company upped their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. dropped their price objective on Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating for the company in a research report on Monday, September 16th. Finally, Robert W. Baird reduced their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $124.11.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.